US-CONGRESS HR7970: STOP Nitazenes Act
The STOP Nitazenes Act (HR 7970) has been forwarded to the full committee, advancing legislation that would permanently schedule nitazenes as controlled substances, imposing new registration, reporting, and recordkeeping requirements on pharmacies handling these substances.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies should confirm how it applies to their specific situation before acting. There is a time constraint attached: Upon enactment (likely within 90 days of passage); monitor committee schedule for final vote.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Nitazenes (a class of synthetic opioids) would be permanently added to Schedule I, requiring DEA registration, suspicious order monitoring, and PDMP reporting for any pharmacy that compounds, dispenses, or handles these substances.
Who it affects
Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies
What you must do
Review current inventory and supply chain for any nitazene compounds; ensure DEA registration covers Schedule I substances; update PDMP reporting protocols; train staff on new recordkeeping and diversion prevention requirements.
Deadline
Upon enactment (likely within 90 days of passage); monitor committee schedule for final vote.
Source: https://www.congress.gov/bill/119th-congress/house-bill/7970
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- DEA warns Georgia pharmacies that selling medical marijuana is illegal - AJC.com
- Kentucky proposes changes to buprenorphine prescribing, dispensing rules - Public News Service
- US-CONGRESS HR4993: Joe Fiandra Access to Home Infusion Act of 2025
- Ohio Board of Pharmacy to increase purchase limits for medical marijuana program - The Columbus Dispatch
- NYBOP's "Double Down" Turns Into a Double Back: New York Softens Shared Pharmacy Services Requirements for Non-Resident Pharmacies - Quarles